Robert Whitfield | Portfolio Manager
Cytiva

After completing my Undergraduate and Masters studies in Medical Biochemistry at The University of Sheffield, I returned to the same institute to complete a PhD in the Department of Chemical and Biological Engineering, focusing on Mab producing CHO cell lines, in conjunction with Pfizer. I then relocated to Sydney, Australia, where I worked as a R&D Project Leader for a Biosimilar company and then as a Cell Line Development Team Leader for Teva Pharmaceuticals, developing high producing CHO cell lines for the GMP manufacturing of antibody therapeutics. I moved back to the UK in 2020 and in January 2022 I joined Cytiva as a Principal Scientist before moving to the position of Portfolio Manager for Cell Lines in the Viral Vector R&D Team. The focus of our group is the development of cell lines for the production of adeno-associated viral vectors. These cell lines form part of an innovative Cytiva Gene Therapy platform that includes cell culture media, both adherent and suspension bioreactor systems and purification solutions.